Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease

Frontiers in Aging Neuroscience

Volumn 5, Issue DEC, 2013, Pages

  Giannoni, Patrizia ^a   Gaven, Florence ^a   De Bundel, Dimitri ^a   Baranger, Kevin ^b,c   Marchetti Gauthier, Evelyne ^b   Roman, François S ^b   Valjent, Emmanuel ^a   Marin, Philippe ^a   Bockaert, Joël ^a   Rivera, Santiago ^b   Claeysen, Sylvie ^a  

^a INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^b Mediterranée University   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Alpha secretase; Amyloid plaques; G protein coupled receptor; Preventive pharmacotherapy; SAPP alpha; Serotonin

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BRAIN EXTRACT; RS 39604; SEROTONIN 4 ANTAGONIST; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOGENESIS; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CEREBROSPINAL FLUID; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; EXPLORATORY BEHAVIOR; FEMALE; GLIOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PROPHYLAXIS; PROTEIN SECRETION; SINGLE DRUG DOSE;

EID: 84895784577     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2013.00096     Document Type: Article

References (51)

1. Aisen, P. S., Vellas, B., and Hampel, H. (2013). Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat. Rev. Drug Discov. 12, 324. doi: 10.1038/nrd3842-c1.
2. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., et al. (2000). Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421. doi: 10.1016/S0197-4580(00)00124-X.
3. Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N., and Murtagh, F. R. (1995). An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde." Clin. Anat. 8, 429-431. doi: 10.1002/ca.980080612.
4. Ansanay, H., Sebben, M., Bockaert, J., and Dumuis, A. (1992). Characterization of homologous 5-hydroxytryptamine4 receptor desensitization in colliculi neurons. Mol. Pharmacol. 42, 808-816.
5. Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804. doi: 10.1056/NEJMoa1202753.
6. Bevins, R. A., and Besheer, J. (2006). Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory.' Nat. Protoc. 1, 1306-1311. doi: 10.1038/nprot.2006.205.
7. Bockaert, J., Claeysen, S., Compan, V., and Dumuis, A. (2011). 5-HT(4) receptors, a place in the sun: act two. Curr. Opin. Pharmacol. 11, 87-93. doi: 10.1016/j.coph.2011.01.012.
8. Bourdin, J., Desire, L., and Schweighoffer, F. (2008). Methods and tools for the therapy of neurodegenerative pathologies. World Intellect. Prop. Organ. WO 2008/009868 A2, 1-38.
9. Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259. doi: 10.1007/BF00308809.
10. Cachard-Chastel, M., Devers, S., Sicsic, S., Langlois, M., Lezoualc'h, F., Gardier, A. M., et al. (2008). Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice. Behav. Brain Res. 187, 455-461. doi: 10.1016/j.bbr.2007.10.008.
11. Cachard-Chastel, M., Lezoualc'h, F., Dewachter, I., Delomenie, C., Croes, S., Devijver, H., et al. (2007). 5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice. Br. J. Pharmacol. 150, 883-892. doi: 10.1016/j.bbr.2007.10.008.
12. Cho, S., and Hu, Y. (2007). Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp. Neurol. 203, 274-278. doi: 10.1016/j.expneurol.2006.07.021.
13. Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., et al. (2011). Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proc. Natl. Acad. Sci. U.S.A. 108, 14968-14973. doi: 10.1073/pnas.1107411108.
14. Cochet, M., Donneger, R., Cassier, E., Gaven, F., Lichtenthaler, S. F., Marin, P., et al. (2013). 5-HT(4) Receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. ACS Chem. Neurosci. 4, 130-140. doi: 10.1021/cn300095t.
15. Consolo, S., Arnaboldi, S., Giorgi, S., Russi, G., and Ladinsky, H. (1994). 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport 5, 1230-1232. doi: 10.1097/00001756-199406020-00018.
16. Das, P., Verbeeck, C., Minter, L., Chakrabarty, P., Felsenstein, K., Kukar, T., et al. (2012). Transient pharmacologic lowering of Abeta production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol. Neurodegener. 7, 39. doi: 10.1186/1750-1326-7-39.
17. Eglen, R. M., Bonhaus, D. W., Johnson, L. G., Leung, E., and Clark, R. D. (1995). Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. Br. J. Pharmacol. 115, 1387-1392. doi: 10.1111/j.1476-5381.1995.tb16628.x.
18. Fahrenholz, F. (2007). Alpha-secretase as a therapeutic target. Curr. Alzheimer Res. 4, 412-417. doi: 10.2174/156720507781788837.
19. Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., et al. (2005). Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117. doi: 10.1016/S0140-6736(05)67889-67880.
20. Freret, T., Bouet, V., Quiedeville, A., Nee, G., Dallemagne, P., Rochais, C., et al. (2012). Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice. Behav. Brain Res. 230, 304-308. doi: 10.1016/j.bbr.2012.02.012.
21. Gandy, S. (2011). Perspective: prevention is better than cure. Nature 475, S15. doi: 10.1038/475S15a.
22. Girard, S. D., Baranger, K., Gauthier, C., Jacquet, M., Bernard, A., Escoffier, G., et al. (2013). Evidence for early cognitive impairment related to frontal cortex in the 5XFAD mouse model of Alzheimer's disease. J. Alzheimers. Dis. 33, 781-796. doi: 10.3233/JAD-2012-120982.
23. Glenner, G. G., and Wong, C. W. (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890. doi: 10.1016/S0006-291X(84)80190-4.
24. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. doi: 10.1126/science.1072994.
25. Hashimoto, G., Sakurai, M., Teich, A. F., Saeed, F., Aziz, F., and Arancio, O. (2012). 5-HT(4) receptor stimulation leads to soluble AbetaPPalpha production through MMP-9 upregulation. J. Alzheimers Dis. 32, 437-445. doi: 10.3233/JAD-2012-111235.
26. Hegde, S. S., Bonhaus, D. W., Johnson, L. G., Leung, E., Clark, R. D., and Eglen, R. M. (1995). RS 39604: a potent, selective and orally active 5-HT4 receptor antagonist. Br. J. Pharmacol. 115, 1087-1095. doi: 10.1111/j.1476-5381.1995.tb15922.x.
27. Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., and Wirths, O. (2012). Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 33, 196 e129-e140. doi: 10.1016/j.neurobiolaging.2010.05.027.
28. Johnson, D. E., Drummond, E., Grimwood, S., Sawant-Basak, A., Miller, E., Tseng, E., et al. (2012). The 5-HT4 agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex as well as the power of stimulated hippocampal theta oscillations. J. Pharmacol. Exp. Ther. 341, 681-691. doi: 10.1124/jpet.112.192351.
29. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., et al. (1987). The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736. doi: 10.1038/325733a0.
30. Kemp, A., and Manahan-Vaughan, D. (2004). Hippocampal long-term depression and long-term potentiation encode different aspects of novelty acquisition. Proc. Natl. Acad. Sci. U.S.A. 101, 8192-8197. doi: 10.1073/pnas.0402650101.
31. Kim, W. K., Kan, Y., Ganea, D., Hart, R. P., Gozes, I., and Jonakait, G. M. (2000). Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J. Neurosci. 20, 3622-3630.
32. Lamirault, L., and Simon, H. (2001). Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors. Neuropharmacology 41, 844-853. doi: 10.1016/S0028-3908(01)00123-X.
33. Letty, S., Child, R., Dumuis, A., Pantaloni, A., Bockaert, J., and Rondouin, G. (1997). 5-HT4 receptors improve social olfactory memory in the rat. Neuropharmacology 36, 681-687. doi: 10.1016/S0028-3908(96)00169-4.
34. Liu, L., and Duff, K. (2008). A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J. Vis. Exp. 21, 960. doi: 10.3791/960.
35. Maillet, M., Robert, S. J., Cacquevel, M., Gastineau, M., Vivien, D., Bertoglio, J., et al. (2003). Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha. Nat. Cell Biol. 5, 633-639. doi: 10.1038/ncb1007.
36. Marchetti, E., Dumuis, A., Bockaert, J., Soumireu-Mourat, B., and Roman, F. S. (2000). Differential modulation of the 5-HT(4) receptor agonists and antagonist on rat learning and memory. Neuropharmacology 39, 2017-2027. doi: 10.1016/S0028-3908(00)00038-1.
37. Marchetti-Gauthier, E., Roman, F. S., Dumuis, A., Bockaert, J., and Soumireu-Mourat, B. (1997). BIMU1 increases associative memory in rats by activating 5-HT4 receptors. Neuropharmacology 36, 697-706. doi: 10.1016/S0028-3908(97)00058-0.
38. Melnikova, I. (2007). Therapies for Alzheimer's disease. Nat. Rev. Drug Discov. 6, 341-342. doi: 10.1038/nrd2314.
39. Morishima-Kawashima, M., Oshima, N., Ogata, H., Yamaguchi, H., Yoshimura, M., Sugihara, S., et al. (2000). Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am. J. Pathol. 157, 2093-2099. doi: 10.1016/S0002-9440(10)64847-X.
40. Morris, J. C., and Price, J. L. (2001). Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci. 17, 101-118. doi: 10.1385/JMN:17:2:101.
41. Mullard, A. (2012). Sting of Alzheimer's failures offset by upcoming prevention trials. Nat. Rev. Drug Discov. 11, 657-660. doi: 10.1038/nrd3842.
42. Nitsch, R. M., Slack, B. E., Wurtman, R. J., and Growdon, J. H. (1992). Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304-307. doi: 10.1126/science.1411529.
43. Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., et al. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140. doi: 10.1523/JNEUROSCI.1202-06.2006.
44. Reynolds, G. P., Mason, S. L., Meldrum, A., De Keczer, S., Parnes, H., Eglen, R. M., et al. (1995). 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br. J. Pharmacol. 114, 993-998. doi: 10.1111/j.1476-5381.1995.tb13303.x.
45. Rowe, C. C., and Villemagne, V. L. (2013). Brain amyloid imaging. J. Nucl. Med. Technol. 41, 11-18. doi: 10.2967/jnumed.110.076315.
46. Sperling, R. A., Karlawish, J., and Johnson, K. A. (2013). Preclinical Alzheimer disease-the challenges ahead. Nat. Rev. Neurol. 9, 54-58. doi: 10.1038/nrneurol.2012.241.
47. Tesseur, I., Pimenova, A. A., Lo, A. C., Ciesielska, M., Lichtenthaler, S. F., De Maeyer, J. H., et al. (2013). Chronic 5-HT4 receptor activation decreases Abeta production and deposition in hAPP/PS1 mice. Neurobiol. Aging 34, 1779-1789. doi: 10.1016/j.neurobiolaging.2013.01.020.
48. Thathiah, A., and De Strooper, B. (2011). The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat. Rev. Neurosci. 12, 73-87. doi: 10.1038/nrn2977.
49. Tsuchida, Y., Hatao, F., Fujisawa, M., Murata, T., Kaminishi, M., Seto, Y., et al. (2011). Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-inflammatory actions via alpha7nACh receptors on muscularis macrophages associated with postoperative ileus. Gut 60, 638-647. doi: 10.1136/gut.2010.227546.
50. Wyss-Coray, T., and Rogers, J. (2012). Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2, a006346. doi: 10.1101/cshperspect.a006346.
51. Zeinstra, E. M., Wilczak, N., Wilschut, J. C., Glazenburg, L., Chesik, D., Kroese, F. G., et al. (2006). 5HT4 agonists inhibit interferon-gamma-induced MHC class II and B7 costimulatory molecules expression on cultured astrocytes. J. Neuroimmunol. 179, 191-195. doi: 10.1016/j.jneuroim.2006.06.012.